The DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
BRAFE600 in benign and malignant human tumours
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 18×
“Although a large proportion of common acquired naevi harbour mutant BRAF, hardly any such mutations have been identified in Spitz naevi, which typically harbour HRAS mutations and/or amplification (see below; Bastian et al., 2000).”
BackgroundInfluentialA biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
The limited in vitro lifetime of human diploid cell strains
Hayflick, L. (1965) · Experimental Cell Research · doi:10.1016/0014-4827(65)90211-9 · Cited by 5,876
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 4×
“Importantly, oncogene-induced senescence is accompanied by the activation or induction of several tumour suppressors, including p16, ARF, p53 and p21 (Serrano et al., 1997).”
BackgroundInfluentialWilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804 · cited 2×
“More than two decades ago, it was observed that mutationally activated RAS, introduced in untransformed fibroblasts, induced cell cycle arrest rather than oncogenic transformation (Land et al., 1983; Franza et al., 1986).”
BackgroundDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Such DDR has been demonstrated also in premalignant lesions in vivo, which often harbour a significant pool of proliferating cells (Bartkova et al., 2005; Gorgoulis et al., 2005; Bartkova et al., 2006; Di Micco et al., 2006).”
BackgroundRb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 1×
“They also form senescence-associated heterochromatic foci (SAHF), stable pRB-dependent heterochromatin structures that repress E2F target genes, thus contributing to the irreversibility of senescence (Narita et al., 2003).”
BackgroundBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 20×
“BRAFE600 can also transform human diploid fibroblasts (HDFs) in the context of a defined set of genetic lesions namely, hTert, SV40 small t (st) and disruption of the pRB and p53 pathways, as shown Oncogene previously for RASV12 (Hahn et al., 2002; Michaloglou et al., 2005).”
BackgroundInfluentialSelf-citationActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 2×
“Recent data reveal that cells undergoing oncogeneinduced senescence in vitro display signs of a DDR, which is causally involved in senescence induction (Bartkova et al., 2006; Di Micco et al., 2006; Mallette et al., 2007).”
BackgroundOncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garre’, M., Giovanni Nuciforo, P., Bensimon, A., et al. (2006) · Nature · doi:10.1038/nature05327 · Cited by 1,821 · cited 2×
“Recent data reveal that cells undergoing oncogeneinduced senescence in vitro display signs of a DDR, which is causally involved in senescence induction (Bartkova et al., 2006; Di Micco et al., 2006; Mallette et al., 2007).”
BackgroundHigh frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Somatic Activation of KIT in Distinct Subtypes of Melanoma
Curtin, J. A., Busam, K., Pinkel, D., & Bastian, B. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2984 · Cited by 1,616
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482 · cited 4×
“This is accompanied by the induction of the senescenceassociated protein ARF in a subset of the cells, as well as by a newly discovered senescence marker, DEC-1 (Collado et al., 2005).”
BackgroundResultInfluentialMelanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371 · cited 3×
“Several MEK inhibitors are currently tested in clinical trials in melanoma patients (reviewed in Gray-Schopfer et al., 2007).”
BackgroundBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228
MITF: master regulator of melanocyte development and melanoma oncogene
Levy, C., Khaled, M., & Fisher, D. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.008 · Cited by 1,169 · cited 2×
“…functions (Rowland and Peeper, 2006): it can act as a tumour suppressor by inducing antiproliferative proteins such as p16INK4a and p21CIP1, and as an oncogene by stimulating proliferation- and survival-promoting genes (including BCL2, TBX2 and CDK2) (reviewed in Levy et al., 2006) (Figure 1).”
BackgroundCellular Senescence in Aging Primates
Herbig, U., Ferreira, M., Condel, L., Carey, D., & Sedivy, J. M. (2006) · Science · doi:10.1126/science.1122446 · Cited by 1,101 · cited 2×
“Replicative senescence denotes the phenomenon of irreversible proliferative arrest, first described for cells aged in culture (Hayflick, 1965) and more recently also in vivo (Herbig et al., 2006).”
BackgroundCoordinating ERK/MAPK signalling through scaffolds and inhibitors
Kolch, W. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1743 · Cited by 1,070
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
The INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 996
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Lin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.19.3008 · Cited by 945
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation
Stork, P. J. S., & Schmitt, J. M. (2002) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)02294-8 · Cited by 897
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
Kondo, T., Ezzat, S., & Asa, S. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1836 · Cited by 893
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Senescence of human fibroblasts induced by oncogenic Raf
Zhu, J., Woods, D., McMahon, M., & Bishop, J. M. (1998) · Genes & Development · doi:10.1101/gad.12.19.2997 · Cited by 826
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818 · cited 2×
“Germline mutations in p16INK4a and CDK4 (CDK4R24C) are associated with familial melanoma (Hussussian et al., 1994; Zuo et al., 1996) and p16INK4a knockout mice treated with DMBA develop, among other tumours, melanoma (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundGarnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
Kambara, T., Simms, L. A., Whitehall, V. L. J., Spring, K. J., Wynter, C. V. A., Walsh, M. D., Barker, M. A., Arnold, S., McGivern, A., Matsubara, N., et al. (2004) · Gut · doi:10.1136/gut.2003.037671 · Cited by 722
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Máximo, V., Botelho, T., Seruca, R., & Sobrinho-Simões, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206706 · Cited by 679
Determinants of BRAF Mutations in Primary Melanomas
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg123 · Cited by 664 · cited 1×
“The latter melanomas, which typically harbour wt BRAF, generally arise later in life (Maldonado et al., 2003; Cohen et al., 2004; Curtin et al., 2005).”
BackgroundPatton, E. E., Widlund, H. R., Kutok, J. L., Kopani, K. R., Amatruda, J. F., Murphey, R. D., Berghmans, S., Mayhall, E. A., Traver, D., Fletcher, C. D. M., et al. (2005) · Current Biology · doi:10.1016/j.cub.2005.01.031 · Cited by 664
Integrating signals from RTKs to ERK/MAPK
McKay, M. M., & Morrison, D. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210394 · Cited by 621
Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation
Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Sabatini, D. M., DeCaprio, J. A., & Weinberg, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2111-2123.2002 · Cited by 612
Senescence and immortalization: Role of telomeres and telomerase
Shay, J. W., & Wright, W. E. (2005) · Carcinogenesis · doi:10.1093/carcin/bgh296 · Cited by 610
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome
Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cavé, H., Verloes, A., Okamoto, N., Hennekam, R. C. M., Gillessen-Kaesbach, G., Wieczorek, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1749 · Cited by 599
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., Kester, M., Sandirasegarane, L., & Robertson, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1399 · Cited by 594
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
Heat shock protein 90 as a molecular target for cancer therapeutics
Isaacs, J. S., Xu, W., & Neckers, L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00029-1 · Cited by 577
Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome
Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., McCormick, F., & Rauen, K. A. (2006) · Science · doi:10.1126/science.1124642 · Cited by 571
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A. (2001) · Nature · doi:10.1038/35092584 · Cited by 568 · cited 2×
“, 1996) and p16 knockout mice treated with DMBA develop, among other tumours, melanoma (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundSelf-citationHoek, K. S., Schlegel, N. C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., Weber, B. L., Nathanson, K. L., Phillips, D. J., Herlyn, M., et al. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00322.x · Cited by 555
KLF4, p21 and context-dependent opposing forces in cancer
Rowland, B. D., & Peeper, D. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1780 · Cited by 551
Self-citationMalignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
A negative feedback signaling network underlies oncogene-induced senescence
Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.003 · Cited by 501
Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus.
Rapp, U. R., Goldsborough, M. D., Mark, G. E., Bonner, T. I., Groffen, J., Reynolds, F. H., & Stephenson, J. R. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4218 · Cited by 483
Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 481
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
Guldberg, P., Straten, P. T., Birck, A., Ahrenkiel, V., Kirkin, A. F., & Zeuthen, J. (1997) · PubMed · Cited by 480
Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage
Goding, C. R. (2000) · Genes & Development · doi:10.1101/gad.14.14.1712 · Cited by 471
Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
Ciampi, R., Knauf, J. A., Kerler, R., Gandhi, M., Zhu, Z., Nikiforova, M. N., Rabes, H. M., Fagin, J. A., & Nikiforov, Y. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523237 · Cited by 461
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457
Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Mutations and Copy Number Increase of HRAS in Spitz Nevi with Distinctive Histopathological Features
Bastian, B. C., LeBoit, P. E., & Pinkel, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64609-3 · Cited by 455
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 455
The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338
King, A. J., Sun, H., Diaz, B., Barnard, D., Miao, W., Bagrodia, S., & Marshall, M. S. (1998) · Nature · doi:10.1038/24184 · Cited by 443
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation
Gupta, P. B., Kuperwasser, C., Brunet, J.-P., Ramaswamy, S., Kuo, W.-L., Gray, J. W., Naber, S. P., & Weinberg, R. A. (2005) · Nature Genetics · doi:10.1038/ng1634 · Cited by 439
The gene expression signatures of melanoma progression
Haqq, C., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D., Pulliam, B. L., Federman, S., Miller, J. R., Allen, R. E., Singer, M. I., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501564102 · Cited by 433
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426
Regulation and Role of Raf-1/B-Raf Heterodimerization
Rushworth, L. K., Hindley, A. D., O'Neill, E., & Kolch, W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2262-2272.2006 · Cited by 418
Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X.-H., Refetoff, S., Nikiforov, Y. E., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0047 · Cited by 414
The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence
Mallette, F. A., Gaumont-Leclerc, M.-F., & Ferbeyre, G. (2007) · Genes & Development · doi:10.1101/gad.1487307 · Cited by 406
Mechanisms of regulating the Raf kinase family
Chong, H., Vikis, H. G., & Guan, K.-L. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00139-0 · Cited by 405
The power and the promise of oncogene-induced senescence markers
Collado, M., & Serrano, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1884 · Cited by 404 · cited 1×
“This could serve as a diagnostic tool, indicating tumour stage or aggressiveness (Collado and Serrano, 2006), although it would probably require better-defined senescence markers.”
BackgroundCooperative effects of INK4a and ras in melanoma susceptibility in vivo
Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner, J. W., & DePinho, R. A. (1997) · Genes & Development · doi:10.1101/gad.11.21.2822 · Cited by 402
Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression
Carreira, S., Goodall, J., Aksan, I., La Rocca, S. A., Galibert, M.-D., Denat, L., Larue, L., & Goding, C. R. (2005) · Nature · doi:10.1038/nature03269 · Cited by 395
Cellular senescence in naevi and immortalisation in melanoma: a role for p16?
Gray-Schopfer, V. C., Cheong, S. C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z. A., Marais, R., Wynford-Thomas, D., & Bennett, D. C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603283 · Cited by 394
Giordano, T. J., Kuick, R., Thomas, D. G., Misek, D. E., Vinco, M., Sanders, D., Zhu, Z., Ciampi, R., Roh, M., Shedden, K., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208822 · Cited by 383
Oncogene-Induced Cell Senescence — Halting on the Road to Cancer
Mooi, W. J., & Peeper, D. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062285 · Cited by 371
Self-citationCritical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase.
Fabian, J. R., Daar, I. O., & Morrison, D. K. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.11.7170 · Cited by 353
Congenital Melanocytic Nevi Frequently Harbor NRAS Mutations but no BRAF Mutations
Bauer, J., Curtin, J. A., Pinkel, D., & Bastian, B. C. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700490 · Cited by 351
Denoyelle, C., Abou-Rjaily, G., Bezrookove, V., Verhaegen, M., Johnson, T. M., Fullen, D. R., Pointer, J. N., Gruber, S. B., Su, L. D., Nikiforov, M. A., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1471 · Cited by 349 · cited 11×
“Although both BRAFE600 and RASV12 induce p16INK4a, the subsequent premature senescence cannot be prevented by p16INK4a knockdown, at least in cultured human cells (Voorhoeve and Agami, 2003; Michaloglou et al., 2005; Denoyelle et al., 2006).”
BackgroundInfluentialMC1R Germline Variants Confer Risk for BRAF -Mutant Melanoma
Landi, M. T., Bauer, J., Pfeiffer, R. M., Elder, D. E., Hulley, B., Minghetti, P., Calista, D., Kanetsky, P. A., Pinkel, D., & Bastian, B. C. (2006) · Science · doi:10.1126/science.1127515 · Cited by 346
Forbes, S., Clements, J., Dawson, E., Bamford, S., Webb, T., Dogan, A., Flanagan, A., Teague, J., Wooster, R., Futreal, P. A., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602928 · Cited by 331
Busca, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2900 · Cited by 326
Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors
Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2423 · Cited by 321
BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas.
Chan, T. L., Zhao, W., Leung, S. Y., & Yuen, S. T. (2003) · PubMed · Cited by 319
Short Telomeres Limit Tumor Progression In Vivo by Inducing Senescence
Feldser, D. M., & Greider, C. W. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.026 · Cited by 314
Inhibitors of the HSP90 Molecular Chaperone: Current Status
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)95009-x · Cited by 310
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds
Gruis, N. A., van der Velden, P. A., Sandkuijl, L. A., Prins, D. E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., & Frants, R. R. (1995) · Nature Genetics · doi:10.1038/ng0795-351 · Cited by 310
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., & Rosen, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609973103 · Cited by 308
Ackermann, J., Frutschi, M., Kaloulis, K., McKee, T., Trumpp, A., & Beermann, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2970 · Cited by 306
Dumaz, N., Hayward, R., Martin, J., Ogilvie, L., Hedley, D., Curtin, J. A., Bastian, B. C., Springer, C., & Marais, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4227 · Cited by 304
Yang, S., Farraye, F. A., Mack, C., Posnik, O., & O’Brien, M. J. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000141404.56839.6a · Cited by 286
A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family
Randerson-Moor, J. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.1.55 · Cited by 281
Epigenetic Silencing of the PTEN Gene in Melanoma
Mirmohammadsadegh, A., Marini, A., Nambiar, S., Hassan, M., Tannapfel, A., Ruzicka, T., & Hengge, U. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0384 · Cited by 279
New insight into BRAF mutations in cancer
Dhomen, N., & Marais, R. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.005 · Cited by 278
Cancer genetics and drug discovery in the zebrafish
Stern, H. M., & Zon, L. I. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1126 · Cited by 272
Meier, F. (2005) · Frontiers in Bioscience · doi:10.2741/1755 · Cited by 267
Loercher, A. E., Tank, E. M. H., Delston, R. B., & Harbour, J. W. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200410115 · Cited by 266
Regulation of human skin pigmentation and responses to ultraviolet radiation
Miyamura, Y., Coelho, S. G., Wolber, R., Miller, S. A., Wakamatsu, K., Zmudzka, B. Z., Ito, S., Smuda, C., Passeron, T., Choi, W., et al. (2007) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00358.x · Cited by 250
da Rocha Dias, S., Friedlos, F., Light, Y., Springer, C., Workman, P., & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2632 · Cited by 246
Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601
Zhang, B.-H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.20.5429 · Cited by 245
Straume, O., Sviland, L., & Akslen, L. A. (2000) · PubMed · Cited by 238
Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models
Hoeflich, K. P., Gray, D. C., Eby, M. T., Tien, J. Y., Wong, L., Bower, J., Gogineni, A., Zha, J., Cole, M. J., Stern, H. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2720 · Cited by 232
Willmore-Payne, C., Holden, J. A., Tripp, S., & Layfield, L. J. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.03.015 · Cited by 230
Mitsutake, N., Knauf, J. A., Mitsutake, S., Mesa, C., Zhang, L., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3314 · Cited by 228
Redox Regulation in Human Melanocytes and Melanoma
Meyskens Jr., F. L., Farmer, P., & Fruehauf, J. P. (2001) · Pigment Cell Research · doi:10.1034/j.1600-0749.2001.140303.x · Cited by 225
Skin colour and skin cancer –MC1R, the genetic link
Sturm, R. A. (2002) · Melanoma Research · doi:10.1097/00008390-200209000-00001 · Cited by 224
Cooperating oncogenes converge to regulate cyclin/cdk complexes.
Lloyd, A. C., Obermüller, F., Staddon, S., Barth, C. F., McMahon, M., & Land, H. (1997) · Genes & Development · doi:10.1101/gad.11.5.663 · Cited by 224
Mutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions
Yazdi, A. S., Palmedo, G., Flaig, M. J., Puchta, U., Reckwerth, A., Rütten, A., Mentzel, T., Hügel, H., Hantschke, M., Schmid-Wendtner, M.-H., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12559.x · Cited by 221
INK4a‐deficient human diploid fibroblasts are resistant to RAS‐induced senescence
Brookes, S., Rowe, J., Ruas, M., Llanos, S., Clark, P. A., Lomax, M., James, M. C., Vatcheva, R., Bates, S., Vousden, K. H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf289 · Cited by 220
Role of p14ARF in Replicative and Induced Senescence of Human Fibroblasts
Wei, W., Hemmer, R. M., & Sedivy, J. M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.20.6748-6757.2001 · Cited by 217
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.
Gorden, A., Osman, I., Gai, W., He, D., Huang, W., Davidson, A., Houghton, A. N., BUSAM, K. J., & Polsky, D. (2003) · PubMed · Cited by 212
Human melanocyte senescence and melanoma susceptibility genes
Bennett, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206446 · Cited by 212
BRAF alterations are associated with complex mutational profiles in malignant melanoma
Daniotti, M., Oggionni, M., Ranzani, T., Vallacchi, V., Campi, V., Di Stasi, D., Torre, G. D., Perrone, F., Luoni, C., Suardi, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207780 · Cited by 210
The Transcription Network Regulating Melanocyte Development and Melanoma
Vance, K. W., & Goding, C. R. (2004) · Pigment Cell Research · doi:10.1111/j.1600-0749.2004.00164.x · Cited by 209
Emuss, V., Garnett, M., Mason, C., The Cancer Genome Project, & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1683 · Cited by 207
Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors
Ho, C.-L., Kurman, R. J., Dehari, R., Wang, T.-L., & Shih, I.-M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2067 · Cited by 206
BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar, R., Angelini, S., Czene, K., Sauroja, I., Hahka‐Kemppinen, M., Pyrhönen, S. O., & Hemminki, K. (2003) · PubMed · Cited by 205
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations
Chudnovsky, Y., Adams, A. E., Robbins, P. B., Lin, Q., & Khavari, P. A. (2005) · Nature Genetics · doi:10.1038/ng1586 · Cited by 198
Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation
Wellbrock, C., & Marais, R. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505059 · Cited by 196
The tumor-suppressive functions of the human INK4A locus
Voorhoeve, P. M., & Agami, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00223-x · Cited by 194
Sumimoto, H., Miyagishi, M., Miyoshi, H., Yamagata, S., Shimizu, A., Taira, K., & Kawakami, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207812 · Cited by 194
Structure and biological activity of human homologs of the raf/mil oncogene.
Bonner, T. I., Kerby, S. B., Sutrave, P., Gunnell, M. A., Mark, G., & Rapp, U. R. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.6.1400 · Cited by 193
Sensi, M., Nicolini, G., Petti, C., Bersani, I., Lozupone, F., Molla, A., Vegetti, C., Nonaka, D., Mortarini, R., Parmiani, G., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209379 · Cited by 183 · cited 1×
“Although there are some reports of BRAF mutations coinciding with RAS mutations within the same tumour, the oncogenic nature of these mutations and their coexistence in the same cell are not always clear (Davies et al., 2002; Gorden et al., 2003; Kumar et al., 2003b; Sensi et al., 2006).”
BackgroundMicroarray expression profiling in melanoma reveals a BRAF mutation signature
Pavey, S., Johansson, P., Packer, L., Taylor, J., Stark, M., Pollock, P. M., Walker, G. J., Boyle, G. M., Harper, U., Cozzi, S.-J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207563 · Cited by 183
Gray‐Schopfer, V. C., Dias, S. D. R., & Marais, R. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-5865-1 · Cited by 181
BRAF Mutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas
Lima, J., Trovisco, V., Soares, P., Máximo, V., Magalhães, J., Salvatore, G., Santoro, M., Bogdanova, T., Tronko, M., Abrosimov, A., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032224 · Cited by 181
Mercer, K., Giblett, S., Green, S., Lloyd, D., DaRocha Dias, S., Plumb, M., Marais, R., & Pritchard, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2211 · Cited by 179
p16Ink4a in Melanocyte Senescence and Differentiation
Sviderskaya, E. V. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.6.446 · Cited by 179
BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma
Salvatore, G., De Falco, V., Salerno, P., Nappi, T. C., Pepe, S., Troncone, G., Carlomagno, F., Melillo, R. M., Wilhelm, S. M., & Santoro, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2378 · Cited by 172
A melanoma-associated germline mutation in exon 1β inactivates p14ARF
Rizos, H., Puig, S., Badenas, C., Malvehy, J., Darmanian, A. P., Jiménez, L., Milà, M., & Kefford, R. F. (2001) · Oncogene · doi:10.1038/sj.onc.1204728 · Cited by 171
Franza, B. R., Maruyama, K., Garrels, J. I., & Ruley, H. E. (1986) · Cell · doi:10.1016/0092-8674(86)90462-9 · Cited by 166 · cited 1×
“More than two decades ago, it was observed that mutationally activated RAS, introduced in untransformed fibroblasts, induced cell cycle arrest rather than oncogenic transformation (Land et al., 1983; Franza et al., 1986).”
BackgroundB-raf, a New Member of the raf Family, is Activated by DNA Rearrangement
Ikawa, S., Fukui, M., Ueyama, Y., Tamaoki, N., Yamamoto, T. S., & Toyoshima, K. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.6.2651-2654.1988 · Cited by 161
Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells
Huntington, J. T., Shields, J. M., Der, C. J., Wyatt, C. A., Benbow, U., Slingluff, C. L., & Brinckerhoff, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405102200 · Cited by 161
Mesa, C. O., Mirza, M., Mitsutake, N., Sartor, M. A., Medvedovic, M., Tomlinson, C. R., Knauf, J. A., Weber, G. F., & Fagin, J. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0739 · Cited by 151
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines
Bloethner, S., Chen, B., Hemminki, K., Müller‐Berghaus, J., Ugurel, S., Schadendorf, D., & Kumar, R. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi066 · Cited by 151
NAKATO, N., Takata, M., Takayanagi, S., Takashima, S., Lin, J., Murata, H., Fujimoto, A., Hatta, N., & Saida, T. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700366 · Cited by 150
Sviderskaya, E. V., Gray‐Schopfer, V. C., Hill, S. P., Smit, N. P. M., Evans-Whipp, T. J., BOND, J. A., Hill, L., Bataille, V. A., Peters, G., Kipling, D., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.10.723 · Cited by 147
Beck, T. W., Huleihel, M., Gunnell, M., Bonner, T. I., & Rapp, U. R. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.2.595 · Cited by 141
Alterations of the BRAF Gene in Thyroid Tumors
Ciampi, R., & Nikiforov, Y. E. (2005) · Endocrine Pathology · doi:10.1385/ep:16:3:163 · Cited by 138
Tsavachidou, D., Coleman, M. L., Athanasiadis, G., Li, S., Licht, J. D., Olson, M. F., & Weber, B. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1669 · Cited by 137
Ma, K., Ivanov, V. N., Dong, J., & Ronai, Z. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206598 · Cited by 135
Calipel, A., Lefevre, G. M., Pouponnot, C., Mouriaux, F., Eychène, A., & Mascarelli, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308709200 · Cited by 134
Exon 15 BRAF Mutations Are Uncommon in Melanomas Arising in Nonsun-Exposed Sites
Cohen, Y., Rosenbaum, E., Begum, S., Goldenberg, D., Esche, C., Lavie, O., Sidransky, D., & Westra, W. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0562 · Cited by 134
Woods, D. B., Cherwinski, H. M., Venetsanakos, E., Bhat, A., Gysin, S., Humbert, M., Bray, P. F., Saylor, V., & McMahon, M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.9.3192-3205.2001 · Cited by 132
Meier, F. E., Busch, S., Lasithiotakis, K. G., Kulms, D., Garbe, C., Maczey, E., Herlyn, M., & Schittek, B. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07821.x · Cited by 131
Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Collisson, E. A., De, A., Suzuki, H., Gambhir, S. S., & Kolodney, M. S. (2003) · PubMed · Cited by 129
Talve, L., Sauroja, I., Collan, Y. U., Punnonen, K. R. A., & Ekfors, T. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970620)74:3<255::aid-ijc4>3.0.co;2-y · Cited by 127
The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation
GOODALL, J. C., Wellbrock, C., Dexter, T. J., Roberts, K., Marais, R., & Goding, C. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2923-2931.2004 · Cited by 126
Raf kinases: Oncogenesis and drug discovery
Schreck, R., & Rapp, U. R. (2006) · International Journal of Cancer · doi:10.1002/ijc.22144 · Cited by 124
Straume, O., Smeds, J., Kumar, R., Hemminki, K., & Akslen, L. A. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64174-0 · Cited by 124
Serrated Pathway and APC (Conventional)-Type Colorectal Polyps
Goldstein, N. S. (2005) · American Journal of Clinical Pathology · doi:10.1309/87bd0c6ucgug236j · Cited by 121
Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo
Sharpless, N. E., Kannan, K., Xu, J., Bosenberg, M., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206809 · Cited by 116
Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611
Jansen, H. W., Lurz, R., Bister, K., Bonner, T. I., Mark, G. E., & Rapp, U. R. (1984) · Nature · doi:10.1038/307281a0 · Cited by 115
Molhoek, K. R., Brautigan, D. L., & Slingluff, C. L. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-39 · Cited by 115
Molecular Regulation of Melanocyte Senescence
Bennett, D. C., & Medrano, E. E. (2002) · Pigment Cell Research · doi:10.1034/j.1600-0749.2002.02036.x · Cited by 111
Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells
Eskandarpour, M., Kiaii, S., Zhu, C., Castro, J., Sakko, A. J., & Hansson, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.20873 · Cited by 110
Nicke, B., Bastien, J., Khanna, S. J., Warne, P. H., Cowling, V., Cook, S. J., Peters, G., Delpuech, O., Schulze, A., Berns, K., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.038 · Cited by 108 · cited 2×
“, 1997), human ovarian surface epithelial cells (Nicke et al., 2005) and primary human melanocytes (Denoyelle et al.”
BackgroundNormal Human Fibroblasts Are Resistant to RAS-Induced Senescence
Benanti, J. A., & Galloway, D. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2842-2852.2004 · Cited by 103
BRAF and c-kit gene copy number in mutation-positive malignant melanoma
Willmore‐Payne, C., Holden, J. A., Hirschowitz, S. L., & Layfield, L. J. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.01.003 · Cited by 101
Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation
Domingo, E., Espín, E., Armengol, M., Oliveíra, C., Pinto, M., Duval, A., Louis‐Brennetot, C., Seruca, R., Hamelin, R., Yamamoto, H., et al. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10310 · Cited by 100
Could BRAF Mutations in Melanocytic Lesions Arise from DNA Damage Induced by Ultraviolet Radiation?
Thomas, N. E., Berwick, M., & Cordeiro‐Stone, M. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700458 · Cited by 91
Kumar, R., Angelini, S., & Hemminki, K. (2003) · Oncogene · doi:10.1038/sj.onc.1206909 · Cited by 90
B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas
Trovisco, V., Soares, P., & Sobrinho-Simões, M. A. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.03.013 · Cited by 90
Zebisch, A., Staber, P. B., Delavar, A., Bodner, C., Hiden, K., Fischereder, K., Janakiraman, M., Linkesch, W., Auner, H. W., Emberger, W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0115 · Cited by 90
Huebner, K., ar-Rushdi, A., Griffin, C. A., Isobe, M., Kozak, C. A., Emanuel, B. S., Nagarajan, L., Cleveland, J. L., Bonner, T. I., & Goldsborough, M. D. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3934 · Cited by 83
Lack of Association between BRAF Mutation and MAPK ERK Activation in Melanocytic Nevi
Uribe, P., Andrade, L., & González, S. (2005) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700011 · Cited by 81
B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis
Boisvert-Adamo, K., & Aplin, A. E. (2006) · Oncogene · doi:10.1038/sj.onc.1209493 · Cited by 79
p53-related pathways and the molecular pathogenesis of melanoma
Hussein, M. R., Haemel, A. K., & Wood, G. S. (2003) · European Journal of Cancer Prevention · doi:10.1097/00008469-200304000-00002 · Cited by 78
BRAF as a melanoma susceptibility candidate gene?
Laud, K., Kannengiesser, C., Avril, M., Chompret, A., Stoppa‐Lyonnet, D., Desjardins, L., Eychène, A., Démenais, F., Lenoir, G., & Paillerets, B. B. (2003) · PubMed · Cited by 75
p53 immunoreactivity in human malignant melanoma and dysplastic naevi
McGregor, J. M., Yu, C. C. ‐., DUBLIN, E. A., Barnes, D. M., Levison, D. A., & MACDONALD, D. M. (1993) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1993.tb00253.x · Cited by 71
Functional analysis of the regulatory requirements of B-Raf and the B-RafV600E oncoprotein
Brummer, T., Martin, P., Herzog, S., Misawa, Y., Daly, R. J., & Reth, M. G. (2006) · Oncogene · doi:10.1038/sj.onc.1209640 · Cited by 70
Yeh, A. H., Bohula, E. A., & Macaulay, V. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209674 · Cited by 66
Wong, T. H., & Rees, J. L. (2005) · Peptides · doi:10.1016/j.peptides.2004.11.021 · Cited by 66
Absence of exon 15BRAF germline mutations in familial melanoma
Lang, J., Boxer, M., & MacKie, R. M. (2003) · Human Mutation · doi:10.1002/humu.10188 · Cited by 66
Immunohistochemical detection of CDK4 and 9 16INK4proteins in cutaneous malignant melanoma
WANG, Y.-L., UHARA, H., YAMAZAKI, Y., NIKAIDO, T., & SAIDA, T. (1996) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1996.tb07612.x · Cited by 65
V600E B‐Rafはその安定性にHsp90シャペロンを要求し,Hsp90阻害剤への応答として分解される
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D. B., & Rosen, N. X. (2006) · Proceedings of the National Academy of Sciences · Cited by 65
Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi
Papp, T., Schipper, H., Kumar, K., Schiffmann, D., & Zimmermann, R. (2005) · Melanoma Research · doi:10.1097/00008390-200510000-00008 · Cited by 64
Constitutive Activation of the Mitogen-Activated Protein Kinase Signaling Pathway in Acral Melanomas
Takata, M., Goto, Y., Ichii, N., Yamaura, M., Murata, H., Koga, H., Fujimoto, A., & Saida, T. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23812.x · Cited by 63
Mælandsmo, G. M., Holm, R., Fodstad, Ø., Kerbel, R. S., & Flørenes, V. A. (1996) · Europe PMC (PubMed Central) · Cited by 62
Goldstein, S., Moerman, E. J., Fujii, S., & Sobel, B. E. (1994) · Journal of Cellular Physiology · doi:10.1002/jcp.1041610321 · Cited by 59
Casula, M., Colombino, M., Satta, M. P., Cossu, A., Ascierto, P. A., Bianchi‐Scarrà, G., Castiglia, D., Budroni, M., Rozzo, C., Manca, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.112 · Cited by 56
Wilson, R. E., Dooley, T. P., & Hart, I. R. (1989) · PubMed · Cited by 56
Raeve, L. E. D., Claes, A., Ruiter, D. J., van Muijen, G. N. P., Roseeuw, D. I., & van Kempen, L. C. L. T. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.07055.x · Cited by 56
Trotter, M. J., Tang, L., & Tron, V. A. (1997) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.1997.tb00790.x · Cited by 51
Kramer, B. W. W., Götz, R., & Rapp, U. R. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-24 · Cited by 48
Christensen, C., & Guldberg, P. (2005) · Oncogene · doi:10.1038/sj.onc.1208758 · Cited by 48
Mutational analysis of the ARAF gene in human cancers
Lee, J. W., Soung, Y. H., Kim, S. Y., Park, W. S., Nam, S. W., Min, W. S., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Apmis · doi:10.1111/j.1600-0463.2005.apm1130108.x · Cited by 47
Polymorphisms of the BRAF gene predispose males to malignant melanoma.
Meyer, P., Sergi, C. M., & Garbe, C. (2003) · Journal of Carcinogenesis · doi:10.1186/1477-3163-2-7 · Cited by 44
Acute lymphoblastic leukaemia in a patient with cardiofaciocutaneous syndrome
BERG, H. V. D., & Hennekam, R. C. M. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.10.799 · Cited by 39
Senescence and serration: a new twist to an old tale
Minoo, P., & Jass, J. R. (2006) · The Journal of Pathology · doi:10.1002/path.2047 · Cited by 39
Proliferative activity of primary cutaneous melanocytic tumours
Kuwata, T., Kitagawa, M., & Kasuga, T. (1993) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf01607148 · Cited by 38
Exclusion of BRAFV599E as a melanoma susceptibility mutation
Meyer, P., Klaes, R., Schmitt, C. R., Boettger, M. B., & Garbe, C. (2003) · International Journal of Cancer · doi:10.1002/ijc.11199 · Cited by 37
Rauen, K. A. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31315 · Cited by 36
Zuo, H., Nakamura, Y., Yasuoka, H., Zhang, P., Nakamura, M., Mori, I., Miyauchi, A., & Kakudo, K. (2006) · Pathology International · doi:10.1111/j.1440-1827.2007.02050.x · Cited by 35
Miracco, C., Santi, M. M. D., Schürfeld, K., Santopietro, R., Lalinga, A. V., Fimiani, M., BIAGIOLI, M., Brogi, M., Felice, C. D., Luzi, P., et al. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.04600.x · Cited by 31
Cited by
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
Self-citationInsufficient Sleep in Adolescents and Young Adults: An Update on Causes and Consequences
Owens, J., ADOLESCENT SLEEP WORKING GROUP, COMMITTEE ON ADOLESCENCE, Au, R., Carskadon, M., Millman, R., Wolfson, A., Braverman, P. K., Adelman, W. P., Breuner, C. C., et al. (2014) · Pediatrics · doi:10.1542/peds.2014-1696 · Cited by 1,413
Recurrent BRAF mutations in Langerhans cell histiocytosis
Badalian-Very, G., Vergilio, J.-A., Degar, B. A., MacConaill, L. E., Brandner, B., Calicchio, M. L., Kuo, F. C., Ligon, A. H., Stevenson, K. E., Kehoe, S. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279083 · Cited by 1,243
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
Senescence-messaging secretome: SMS-ing cellular stress
Kuilman, T., & Peeper, D. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2560 · Cited by 909
Self-citation
Metadata
- Authors
- Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S.
- Venue
- Oncogene
- Published
- 2007-08-27
- Volume
- 27
- Issue
- 7
- Pages
- 877-895
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2046137334
- Cited by
- 275
- References
- 203
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.